Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody
Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH
Annual Meeting

Oslo, Norway, 3 November 2022

Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company")
announces the progress it has made in designing and developing a portfolio of
novel and potent humanized anti-CD37 monoclonal antibodies with potential for
treating B-cell malignancies or B-cell-driven autoimmune disorders.

Details of the Company's progress in engineering this portfolio are included in
two abstracts published today for presentation as posters at the 64[th] American
Society of Hematology (ASH) Annual Meeting & Exposition (10-13 December 2022 in
New Orleans, LA, USA). The abstracts will also be published online in a November
supplemental issue of Blood, published by The American Society of Hematology.

The abstracts describe how, through antibody engineering, Nordic Nanovector has
developed several humanized anti-CD37 monoclonal antibodies and demonstrated in
preclinical studies their enhanced effector mechanisms, such as antibody
-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular
phagocytosis (ADCP) and longer half-life in the blood.

CD37 is a protein abundant on the surface of B cells but absent in
haematopoietic stem cells and plasma cells. Its expression pattern makes it
attractive as a therapeutic target for B-cell malignancies, including non
-Hodgkin lymphomas and chronic lymphocytic Leukemia and for B-cell-driven
autoimmune disorders, especially where an alternative to standard anti-CD20
immunotherapy is sought.

Jostein Dahle, Co-founder and CSO of Nordic Nanovector, commented: "We are
pleased to present at ASH the initial findings from our preclinical studies with
our novel humanized anti-CD37 antibody portfolio. These antibodies have been
designed to be highly selective for CD37 on B cells and shown to be potent at
depleting these cells as well as enduring in the circulation. There is a
significant unmet clinical need for new therapeutic approaches for patients with
B-cell-driven diseases who do not respond to anti-CD20 therapies. The
encouraging preclinical results we will present at ASH support the further
development of these candidates for B-cell malignancies or B-cell-driven
autoimmune disorders."

Details of the abstracts to be presented at ASH are as follows:

Abstract 1351

Abstract title:                 NNV024, a Humanized Anti-CD37 Antibody with
Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell
Malignancies

Authors:                        R. Generalov et al.

Session Name:              605. Molecular Pharmacology and Drug Resistance:
Lymphoid Neoplasms: Poster I

Date:                            Saturday, December 10

Presentation Time:        5:30 PM - 7:30 PM Eastern time

Location:                       Ernest N. Morial Convention Center, Hall D

Abstract 2679

Abstract title:                 B-Cell Targeting Anti-CD37 Humanized Antibodies
Engineered for Potent Effector Functions and Extended Plasma Half-Life

Authors:                        E. Fiorito et al.

Session Name:              605. Molecular Pharmacology and Drug Resistance:
Lymphoid Neoplasms: Poster II

Session Date:               Sunday, 11 December

Presentation Time:        6:00 PM - 8:00 PM Eastern time

Location:                      Ernest N. Morial Convention Center, Hall D

IR enquiries

Malene Brondberg, interim CEO & CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company's clinical- and preclinical-stage pipeline includes:

  · Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies
incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma
(NHL)